TROPION-Lung01 Study Design and Baseline demographics

Overall Safety Summary Daiichi-Sankyo • • Median treatment duration was 6.7 months with Dato-DXd and 4.1 months with ICC Rate of grade ≥23 TRAES in the Dato-DXd group was less than half that in the ICC group Fewer TRAEs leading to dose reductions or interruptions with Dato-DXd compared with ICC TRAES, n (%) Dato-DXd (n=360) ICC (n=351) All grades 337 (94) 303 (86) Grade ≥3 75 (21) 157 (45) Associated with dose reduction 75 (21) 106 (30) Associated with dose interruption 43 (12) 86 (25) • Associated with discontinuation 9 (3) 9 (3) 0 1 (0.3) Associated with death Serious TRAES 21 (6) 32 (9) Grade ≥3 17 (5) 31 (8) TRAES, treatment-related adverse events. 33

View entire presentation